PIPELINE
Pioneering therapeutics to restore gene networks, starting with siRNA for cardiometabolism.
Reset Platform Collaborations
PARKINSON’S
Computational target discovery delivery, validation plan.
SKIN AGING
Computational target discovery delivery and early validation.
JUN_01 for Type 2 Diabetes
Junevity’s lead program, JUN_01, is a novel liver-targeted siRNA in T2D to treat the millions of patients not at target HbA1c and hs-CRP despite GLP-1s and other medications. In non-human primate studies, JUN_01 has shown improvements in glycemic control, insulin sensitivity and inflammatory markers on top of GLP-1s. JUN_01 could be the first T2D medicine with ultra-infrequent dosing of 1-2x per year to address adherence challenges. Junevity is preparing for first-in-human clinical trials in Q4 2026.
Our Long-Term Vision
Our vision is to advance siRNA therapeutics that restore gene networks and unlock new possibilities for treating complex diseases.
